Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 20/20 | 0.59 |
| ▸ | OXTR | P30559 | 2/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519013 | 0.98 | AVPR1B (0.56) | AVPR1BOXTRAVPR1A | |
| SCHEMBL6521613 | 0.98 | AVPR1B (0.59) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL6517789 | 0.95 | AVPR1B (0.58) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL6521623 | 0.95 | AVPR1B (0.56) | AVPR1BOXTRAVPR1A | |
| SCHEMBL3268114 | 0.95 | AVPR1B (0.59) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL6517793 | 0.94 | AVPR1B (0.51) | AVPR1BOXTRAVPR1A | |
| SCHEMBL6521552 | 0.94 | AVPR1B (0.59) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL6521677 | 0.94 | AVPR1B (0.59) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL6517783 | 0.94 | AVPR1B (0.61) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL15641570 | 0.93 | AVPR1B (0.55) | AVPR1BOXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703774-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-22 | — | — | US | claimed |
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2016-12-15 | — | — | US | disclosed |
| US-9422264-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-23 | — | — | US | disclosed |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| US-8703774-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABOTT GMBH & CO KG (DE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885OXTR 4/4885AVPR1A 3/4885 |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885OXTR 4/4885AVPR1A 3/4885 |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885OXTR 4/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.